Serametrix Gains CLIA Certification for MDSC-based Blood Test for Predicting Response to Immunotherapy in Cancer Patients

News Clinicians will now be able to use the blood test to help select the best treatment pathways and drug combinations for their patients. The assay, which utilizes flow cytometry, is carried out at a testing facility in Carlsbad, CA. Contributed Author:  Serametrix Topics:  Medical Diagnostics